{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T07:44:27Z","timestamp":1762760667188},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> To further evaluate mephenytoin as a probe for CYP2C19 phenotyping.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Healthy subjects (<jats:italic>n<\/jats:italic>\u2003=\u20032638) were phenotyped using the urinary <jats:italic>(S)\u2010<\/jats:italic>mephenytoin to <jats:italic>(R)\u2010<\/jats:italic>mephenytoin ratio. This method was evaluated for (a) the stability of the S\/R\u2010ratio following sample storage, (b) the intraindividual reproducibility of the ratio, and (c) the occurrence of adverse events.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> After prolonged storage, the S\/R\u2010ratio of samples from extensive metabolisers (EM) increased up to 85%. In 1.5% of the cases (1 out 66), this led to incorrect classification of phenotype. In EMs, but not in poor metabolisers (PMs), the S\/R\u2010ratio increased after acid treatment. The intraindividual reproducibility of the mephenytoin phenotyping procedure was 28%. No major side\u2010effects were observed and there was no relationship between the incidence of side\u2010effects and the phenotype of the subject.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> After prolonged storage the S\/R\u2010ratio significantly increased in EMs and, although low, the risk of incorrect classification should not be ignored. Our data support the use of mephenytoin as a safe drug for CYP2C19 phenotyping.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2001.01331.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:41:35Z","timestamp":1047357695000},"page":"471-474","source":"Crossref","is-referenced-by-count":14,"title":["Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra\u2010individual reproducibility and occurrence of adverse events"],"prefix":"10.1111","volume":"51","author":[{"given":"Wim J.","family":"Tamminga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Wemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berend","family":"Oosterhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Wieling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rokus A.","family":"De Zeeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lou F. M. H.","family":"De Leij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H. G.","family":"Jonkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"OosterhuisB TammingaWJ WemerJ et al.Mephenytoin as a marker for CYP219 enzyme activity: influence of analytical factors on the outcome of phenotyping.Proceedings of \u2018European Symposium on the Prediction of Drug Metabolism in Man: Progress and Problems\u2019. COST B1 Li\u00e8ge Belgium 19\u201320 May:197\u2013200 1998."},{"key":"e_1_2_6_3_2","first-page":"662","article-title":"Phenotypic differences in mephenytoin pharmacokinetics in normal subjects","volume":"243","author":"Wedlund PJ","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541938"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90241-4"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05542.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04099.x"},{"key":"e_1_2_6_8_2","first-page":"277","article-title":"Pharmacogenetic association between the formation of 4\u2010hydroxymephenytoin and a new metabolite of S\u2010mephenytoin in man","volume":"5","author":"Wedlund PJ","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199710000-00003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199210000-00007"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050615"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.63"},{"key":"e_1_2_6_13_2","unstructured":"World Health Organization.WHO adverse reaction dictionary. WHO Collaborating Centre for International Drug Monitoring; Uppsala1995."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2001.01331.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2001.01331.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2001.01331.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:10:56Z","timestamp":1697523056000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2001.01331.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1365-2125.2001.01331.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2001.01331.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}